ArticleNature communications2019
A functional subset of CD8
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 78 citations in OpenAlex.
- Review
- Article
- Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.Research square · 2026Article
- The SIRP family: from structural diversity and signaling mechanisms to implications in immune-related disease targeted therapeutics.Frontiers in immunology · 2026Review
- CD47 monoclonal antibodies differ in their capacity to induce immune response.European journal of microbiology & immunology · 2025Article
- Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption.Cancer discovery · 2025Article
- Loss of NR2F6 Protects from Salmonella Typhimurium Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immune checkpoint molecules signal regulatory protein alpha in the development of hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Review
- CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion.Acta biochimica et biophysica Sinica · 2025Review
- Article
- Novel immunotherapy for gastric cancer: targeting the CD47-SIRPα axis.Cancer metastasis reviews · 2025Review
- Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.Signal transduction and targeted therapy · 2024Review
- Effects of parity and early pregnancy on peripheral blood leukocytes in dairy cattle.bioRxiv : the preprint server for biology · 2024Article
- Article
- Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.Cell communication and signaling : CCS · 2024Article
- Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of COVID-19-related cancers.Heliyon · 2023Review
- SIRPα blockade improves the antitumor immunity of radiotherapy in colorectal cancer.Cell death discovery · 2023Article
- Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma.Cancer cell · 2022Article
- CD47/SIRPα axis: bridging innate and adaptive immunity.Journal for immunotherapy of cancer · 2022Review
- Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.Cancer immunology, immunotherapy : CII · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Lara M MyersLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, MT, 59840, USA.
Michal Caspi TalInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0003-2550-6246
Laughing Bear Torrez DulgeroffInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Aaron B CarmodyResearch Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, 59840, USA.
Ronald J MesserLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, MT, 59840, USA.
Gunsagar GulatiInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Ying Ying YiuInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Matthew M StaronResearch Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, 59840, USA.
Cesar Lopez AngelDeparment of Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Rahul SinhaInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Maxim MarkovicInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Edward A PhamInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Benjamin FramDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Aijaz AhmedDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Aaron M NewmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-1857-8172
Jeffrey S GlennDepartment of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Mark M DavisDeparment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0001-6868-657X
Susan M KaechDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, 06520, USA.
Irving L WeissmanInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-9077-7467
Kim J HasenkrugLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, Hamilton, MT, 59840, USA. khasenkrug@nih.gov.ORCID http://orcid.org/0000-0001-8523-4911
Stanford University · USRocky Mountain Research (United States) · USAbbVie (United States) · USSalk Institute for Biological Studies · US
Funding
Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MViral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Ye Zheng · 1985 to 2026
$82.8MTranslational Incubator CoreU19AI109662 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2014 to 2019
$28.6MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MImmunology And Pathology Of Acute Murine Leukemia Virus InfectionsZIAAI000753 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2022
$8.1MInterrogation of individual cells to identify progenitors and their nichesU01HL099999 · NHLBI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2009 to 2015
$7.8MMOLECULAR CHARACTERIZATION OF ACUTE MYELOID LEUKEMIAR01CA086017 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2000 to 2015
$5.5MHIV Infection in Humanized MiceZIAAI001141 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2011 to 2019
$4.2MStructure-function determination of the Hepatitis C Virus negative RNA strand's 3'-terminal sequenceF30DK099017 · NIDDK · STANFORD UNIVERSITY · PI PHAM, EDWARD ANHOA · 2013 to 2015
$98kImmunotherapy targeting the CD47-SIRPα axis to promote immune clearance of chronic infectionF32AI124558 · NIAID · STANFORD UNIVERSITY · PI TAL, MICHAL CASPI · 2016 to 2017
$83kNCI NIH HHS P30 CA014195NCI NIH HHS R01 CA086017NHLBI NIH HHS U01 HL099999NIAID NIH HHS F32 AI124558NIAID NIH HHS T32 AI007290NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI109662NIDDK NIH HHS F30 DK099017
Abstract
Prolonged exposure of CD8
Indexed as
AnimalsArenaviridae InfectionsCD8-Positive T-LymphocytesFemaleGene ExpressionGene Expression ProfilingHost-Pathogen InteractionsHumansLymphocyte ActivationLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMice, Inbred C57BLMice, TransgenicReceptors, ImmunologicT-Lymphocytes, CytotoxicReceptors, ImmunologicSirpa protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.